License agreement under which the Company obtained a license under patents and know-how of Zenas to develop and commercialize products targeting IGF-1R in Greater China; upfront fee paid and additional milestone and royalty payments possible.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Samantha (Ying) Du
Also a director
Founder, Chief Executive Officer, Chairperson of the Board of Directors
|
61 | Not stated | Not stated | $10,677,221 | |
|
Yajing Chen
Chief Financial Officer
|
58 |
Since 2023
3 years
|
Not stated | $3,185,488 | |
|
Josh Smiley
President and Chief Operating Officer
|
56 | Not stated | Not stated | Not reported | |
|
F. Ty Edmondson
Chief Legal Officer
|
60 |
Since 2020
6 years
|
2020 | Not reported | |
|
Frazor Titus Edmondson III
Chief Legal Officer
Title from the Form 4 dated Jun 25, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Rafael G. Amado
President, Head of Global Research and Development
|
62 |
Since 2024
2 years
|
2022 | $4,010,205 | |
|
Yizhe Wang
Operating Partner
Title from the Form 4 dated May 11, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
License agreement under which the Company obtained a license under patents and know-how of Zenas to develop and commercialize products targeting IGF-1R in Greater China; upfront fee paid and additional milestone and royalty payments possible.
Loading...